Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This study will investigate the safety, pharmacology, and activity of atezolizumab in combination with immunotherapy agents with or without an anti-CD20 agent (i.e., obinutuzumab) in patients with relapsed or refractory (R/R) follicular lymphoma (FL). The first immunotherapy molecule investigated will be emactuzumab (Arm A) in two combinations.
Sex
Ages
Volunteers
Inclusion criteria
Inclusion Criteria Specific to Obinutuzumab-Containing Cohorts
Exclusion criteria
Exclusion Criteria Specific to Obinutuzumab-Containing Cohorts:
Hypersensitivity to obinutuzumab
Primary purpose
Allocation
Interventional model
Masking
0 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal